Internal Medicine · Valencia, CA
NPI
1487856779
Since 2007
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
27235 Tourney Rd Ste 2400
Valencia, CA, 91355
Phone (661) 255-5350
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
85,283 services
Medicare patients, 2024
597
Average age 73
Drug cost, 2024
$3.5M
955 prescriptions
Company payments, 2025
$107K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rena D Callahan was code J0897 (injection, denosumab, 1 mg), 7,860 times for 30 patients. In total Rena D Callahan billed 85,283 services in 126 codes, and Medicare paid $1.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-01-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 7,860 | 30 | $20.52 | $161K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 7,050 | 15 | $0.11 | $793 |
| J9394 Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | Office | 1,500 | 20 | $21.15 | $32K |
| J9395 Injection, fulvestrant, 25 mg | Office | 1,400 | 18 | $6.38 | $8,929 |
| 99214 Office E&M - Established | Office | 1,121 | 409 | $102.09 | $114K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 942 | 26 | $0.09 | $84.74 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 827 | 387 | $13.22 | $11K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 600 | 20 | $0.66 | $398 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 552 | 17 | $0.07 | $40.88 |
| 85025 Blood Count | Office | 431 | 145 | $7.61 | $3,280 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 322 | 55 | $0.51 | $164 |
| 96402 Chemotherapy Administration | Office | 297 | 25 | $30.64 | $9,101 |
| 96375 Injection Administration | Office | 286 | 41 | $13.80 | $3,948 |
| 36415 Venipuncture Blood Collection | Office | 233 | 91 | $8.65 | $2,015 |
| 96413 Chemotherapy Administration | Office | 226 | 59 | $115.14 | $26K |
By year: 2022 $1.7M for 78,794 services; 2023 $1.9M for 87,087 services; 2024 $1.8M for 85,283 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 431 | 145 | $7.61 | $3,280 |
| 36415 Venipuncture Blood Collection | 233 | 91 | $8.65 | $2,015 |
Medicare prescription drug claims, 2024
In 2024, the drug Rena D Callahan prescribed most often to Medicare patients was Anastrozole, with 200 prescriptions and refills. In total Rena D Callahan wrote 955 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 200 | 570 | 74 | $4,381 |
| Letrozole Generic | 62 | 138 | 18 | $1,474 |
| Tamoxifen Citrate Generic | 60 | 172 | 22 | $1,731 |
| Verzenio Abemaciclib | 55 | 55 | Under 11 | $733K |
| Exemestane Generic | 37 | 107 | 13 | $6,239 |
| Kisqali Ribociclib Succinate | 33 | 33 | Under 11 | $422K |
| Eliquis Apixaban | 27 | 41 | Under 11 | $24K |
| Lorazepam Generic | 24 | 27 | Under 11 | $156 |
| Pantoprazole Sodium Generic | 22 | 58 | 11 | $458 |
| Truqap Capivasertib | 21 | 21 | Under 11 | $432K |
| Everolimus Generic | 21 | 21 | Under 11 | $85K |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | 21 | 21 | Under 11 | $143K |
| Jakafi Ruxolitinib Phosphate | 18 | 18 | Under 11 | $301K |
| Hydroxyurea Generic | 16 | 45 | Under 11 | $452 |
| Zolpidem Tartrate Generic | 15 | 15 | Under 11 | $58.04 |
Brand drugs: 284 claims; generic drugs: 671 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rena D Callahan $107K ($107K in general payments such as food, travel and fees) from 8 companies. The largest payer was Gilead Sciences, Inc. with $39K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.